Evotec SE EVT.DE
Quarterly and annual results for Evotec stock (EVT.DE) since 2023: revenue, earnings, balance sheet, cash flow and management guidance from IR documents, every figure with its source. As of 04/2026, quarterly reporting. Latest reading: Net cash to net debt, Guidance cut, Divestiture.
Net cash to net debt Guidance cut strategy: Divestiture
Published by Michael Wirl · About us · Methodology
The new quarter, monitored by AI. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Advertisement
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.
Evotec SE is a drug discovery and development company that partners with pharmaceutical and biotechnology companies to advance programs from early research through clinical development. The company operates across drug discovery alliances, integrated drug creation services, and contract development and manufacturing activities, with its Just – Evotec Biologics subsidiary specializing in biologic drug substance manufacturing using continuous and intensified processes. Revenue is generated through research service fees, milestone and license payments tied to development progress, and manufacturing services, principally under multi-year collaboration agreements with global pharmaceutical and biotechnology partners.
Advertisement
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.
H1 2026 group revenues decreased 19.2% to €300.1m, primarily driven by weak sales conversion across business areas and a challenging market environment 31. Q2 2026 revenue was 143.5m and Q2 net income was -46.6m 133. Adjusted Group EBITDA for H1 2026 deteriorated to a loss of €42.7m from a loss of €1.9m in H1 2025, primarily driven by lower revenues 31. Evotec announced Project Horizon, a business transformation program targeting €75m in run-rate savings by end of 2027 31.
Management commentary on the FY2025 results (IR-Annual):
„Today, Evotec is well positioned to undergo a positive shift from stabilization to value creation and growth.“ – Dr Christian Wojczewski, Chief Executive Officer 29
„None of this would be possible without our people. Their commitment, expertise, and resilience have been central to our progress this year.“ – Dr Christian Wojczewski, Chief Executive Officer 29
Revenue · 2026-Q2144€m−16.2 % vs. 2025-Q2
Net profit · 2026-Q2-47€m−7.1 % vs. 2025-Q2
EPS · 2026-Q2-0.26€−8.3 % vs. 2025-Q2
Revenue trend
Guidance
For FY2030, the company guides Revenue to > € 1 bn (8-12% CAGR) (initiated). 32.
ProfitabilityQ2 2026 operating income was -113.3m, including reorganization costs of €98.9m recognized for Project Horizon provisions and asset impairments, and a separate impairment loss of €42.3m on the Hamburg laboratory building related to a sublease marketing decision 31. Diluted EPS for Q2 2026 was -0.26 133. Q2 free cash flow was -116.3m, while H1 2026 operating free cash flow was negative €111.1m compared to negative €5.3m in H1 2025 31.
LeverageAt end of Q2 2026, net debt was 127.5m and cash was 348.4m, compared to a near-neutral net debt position of -0.5m at end of Q1 2026 133. During H1 2026, Evotec issued €116.1m in convertible bonds due 2033 at a conversion price of €6.5313 per share 31. Total liquidity, including available credit lines, decreased to €465.6m as of H1 2026 31.
Management viewJust – Evotec Biologics launched J.TRAIN, a turnkey continuous manufacturing offering enabling biopharmaceutical companies to deploy Evotec's proprietary continuous processing technology 31. A Bristol Myers Squibb milestone payment of $10m was received following phase 1 initiation of a protein degradation collaboration 31. The Gates Foundation awarded €9.9m in grants for tuberculosis drug discovery and translation 31.
ChangeJust – Evotec Biologics revenues declined 29.3% to €72.3m in H1 2026, primarily due to the Sandoz License sale recognized in Q1 2025; excluding this effect, revenues decreased only 2.3% 31. Full-year 2026 revenue guidance was reduced to €570-610m from prior guidance of €700-780m, with adjusted EBITDA now guided to a loss of €70m to €105m versus prior guidance of €0-40m income 31. Employee headcount decreased 6.2% to 4,461 average globally, reflecting divestitures and Project Horizon workforce reductions; total assets decreased €140m to €1,574m and stockholders' equity decreased €148.1m to €665.6m 31.
Risks (current)Weak sales conversion across all business areas persisted through H1 2026, a pattern that contributed to cash outflows during the period 31. The company carries €272.4m in goodwill whose recoverability is subject to judgment regarding future cash flows and discount rates, and is subject to extensive FDA and regulatory requirements where non-compliance could result in loss of approved supplier status 29. An arbitral court decision in July 2025 requires retroactive lease payments in the low seven-figure range for a not-yet-transferred lease asset, and the biopharmaceutical industry generally remains selective with customers acting cautiously amid economic and geopolitical uncertainties 24 31.
New this reporting periodThe sale of Tubulis GmbH to Gilead Sciences was completed on May 21, 2026, for gross consideration of €93.652m with net proceeds of €89.339m 31. Evotec announced a small molecule preclinical development candidate with Almirall in dermatology in May 2026, and a BARDA project agreement for antibody biomanufacturing optimization was signed in March 2026 31. After period-end, Evotec announced a collaboration with Odyssey Therapeutics for AI-enabled drug discovery in autoimmune and inflammatory diseases in August 2026 31.
Advertisement
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.
Daily candles with news and earnings markers. Loads only on click.
Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Advertisement
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.
Project Horizon strategic restructuring amid a guidance cut and widening operating losses
Evotec launched the Horizon transformation program (32) while the latest quarter shows an operating loss of -113.3m and a net loss of -46.6m on revenue of 143.5m (133); the cost base and profitability path now dominate the equity story.
Evotec launched the Horizon transformation program (32) while the latest quarter shows an operating loss of -113.3m and a net loss of -46.6m on revenue of 143.5m (133); the cost base and profitability path now dominate the equity story.
Discovery & Preclinical Development (D&PD) service demand
D&PD generated 143.5m of quarterly revenue within a first-half segment total of EUR 227.9m, with segment revenue lower year on year (31).
D&PD generated 143.5m of quarterly revenue within a first-half segment total of EUR 227.9m, with segment revenue lower year on year (31).
Just-Evotec Biologics manufacturing (J.POD / J.TRAIN, government contracts)
BARDA project agreement for antibody biomanufacturing optimization (32, 31) and the J.TRAIN turnkey continuous-manufacturing offering (31) signal growing traction in the biologics-manufacturing franchise.
BARDA project agreement for antibody biomanufacturing optimization (32, 31) and the J.TRAIN turnkey continuous-manufacturing offering (31) signal growing traction in the biologics-manufacturing franchise.
Partnership and milestone pipeline
New and extended alliances gaining traction: BMS protein-degradation milestone (31), Odyssey Therapeutics AI collaboration in autoimmune/inflammatory diseases (31) and an Almirall dermatology preclinical candidate (31).
New and extended alliances gaining traction: BMS protein-degradation milestone (31), Odyssey Therapeutics AI collaboration in autoimmune/inflammatory diseases (31) and an Almirall dermatology preclinical candidate (31).
Profitability and cash burn
Operating income of -113.3m and negative free cash flow of -116.3m in the latest quarter, with cash of 348.4m against net debt of 127.5m (133).
Operating income of -113.3m and negative free cash flow of -116.3m in the latest quarter, with cash of 348.4m against net debt of 127.5m (133).
Full-year guidance
Management guidance has been cut, framing a softer near-term revenue and earnings outlook (31).
Management guidance has been cut, framing a softer near-term revenue and earnings outlook (31).
Sector trend: Demand for outsourced drug-discovery and preclinical services is softening, with segment revenue lower and margins compressed, while biologics manufacturing and government-funded programs are the firmer end of the market (31).
Advertisement
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.
Overview: one dot per event · click jumps to the period
2026 · 6 events
2026-Q2 · Apr – Jun 2026
Net cash to net debt 2026-06-30
Net debt position shifted to 127.5m; €116.1m convertible bonds due 2033 issued at conversion price of €6.5313 31
Net debt position shifted to 127.5m; €116.1m convertible bonds due 2033 issued at conversion price of €6.5313 31
Guidance cut 2026-06-30
FY 2026 guidance cut to revenues €570-610m and adjusted EBITDA €(70)-(105)m from prior ranges of €700-780m and €0-40m 31
FY 2026 guidance cut to revenues €570-610m and adjusted EBITDA €(70)-(105)m from prior ranges of €700-780m and €0-40m 31
Divestiture 2026-05-21
Sale of Tubulis GmbH to Gilead Sciences completed for gross consideration of €93.652m, net proceeds €89.339m 31
Sale of Tubulis GmbH to Gilead Sciences completed for gross consideration of €93.652m, net proceeds €89.339m 31
2026-Q1 · Jan – Mar 2026
Revenue decelerating 2026-06-30
Group revenues declined 22% to 156.6m; D&PD down 15%, Just-Evotec Biologics down 38%, partly reflecting prior-year $25m Sandoz license base effect 32
Group revenues declined 22% to 156.6m; D&PD down 15%, Just-Evotec Biologics down 38%, partly reflecting prior-year $25m Sandoz license base effect 32
Guidance confirmed 2026-06-30
FY 2026 guidance confirmed at €700-780m revenue and €0-40m adjusted EBITDA; 2030 mid-term framework targeting >€1bn revenue and >20% EBITDA margin introduced 32
FY 2026 guidance confirmed at €700-780m revenue and €0-40m adjusted EBITDA; 2030 mid-term framework targeting >€1bn revenue and >20% EBITDA margin introduced 32
Strategic pivot 2026-03-10
Project Horizon initiated, targeting global footprint consolidation to 10 sites with €75m run-rate savings expected by end of 2027 32
Project Horizon initiated, targeting global footprint consolidation to 10 sites with €75m run-rate savings expected by end of 2027 32
2025 · 18 events
FY2025 · Jan – Dec 2025
EBITDA turned positive 2025-12-31
EBITDA turned positive for the first time after 1 negative fiscal year (-40.9 to +43.3 EURm). 131
EBITDA turned positive for the first time after 1 negative fiscal year (-40.9 to +43.3 EURm). 131
2025-Q4 · Oct – Dec 2025
„Today, Evotec is well positioned to undergo a positive shift from stabilization to value creation and growth.“ – Dr Christian Wojczewski, Chief Executive Officer 29
financials 2026-03-31
Liquidity increased from €396.8m to €476.4m; net debt position moved to net cash of €(27.7)m following Sandoz transaction proceeds 29
Liquidity increased from €396.8m to €476.4m; net debt position moved to net cash of €(27.7)m following Sandoz transaction proceeds 29
Guidance initiated 2026-03-31
2026 guidance initiated: group revenues €700–780m, Adjusted Group EBITDA €0–40m 29
2026 guidance initiated: group revenues €700–780m, Adjusted Group EBITDA €0–40m 29
Divestiture 2026-03-31
Just – Evotec Biologics EU SAS sold to Sandoz AG effective December 5, 2025 for EUR 225,000k enterprise value plus USD 108m licence consideration and additional potential revenues exceeding USD 300m, completing transition to asset-lighter model 29
Just – Evotec Biologics EU SAS sold to Sandoz AG effective December 5, 2025 for EUR 225,000k enterprise value plus USD 108m licence consideration and additional potential revenues exceeding USD 300m, completing transition to asset-lighter model 29
Operating income turned positive 2025-12-31
Operating income turned positive for the first time after 3 negative periods (-44.5 to +36.1 EURm). 131
Operating income turned positive for the first time after 3 negative periods (-44.5 to +36.1 EURm). 131
Net income turned positive 2025-12-31
Net income turned positive for the first time after 12 negative periods (-43.1 to +14.6 EURm). 131
Net income turned positive for the first time after 12 negative periods (-43.1 to +14.6 EURm). 131
Operating income doubled 2025-12-31
Operating income more than doubled YoY (6.8 to 36.1 EURm, +431%). 131
Operating income more than doubled YoY (6.8 to 36.1 EURm, +431%). 131
2025-Q3 · Jul – Sep 2025
earnings 2025-06-30
Adjusted Group EBITDA deteriorated to €(16.9)m loss in 9M 2025 from €(6.0)m loss in 9M 2024, due to decreased revenues and high fixed costs 23
Adjusted Group EBITDA deteriorated to €(16.9)m loss in 9M 2025 from €(6.0)m loss in 9M 2024, due to decreased revenues and high fixed costs 23
Revenue decelerating 2025-06-30
9M 2025 group revenues decreased 7.1% to €535.1m from €575.7m in 9M 2024, driven by soft demand in Discovery & Preclinical Development segment 23
9M 2025 group revenues decreased 7.1% to €535.1m from €575.7m in 9M 2024, driven by soft demand in Discovery & Preclinical Development segment 23
Guidance cut 2025-06-30
FY2025 revenue guidance revised down to €760–800m from €840–880m; adjusted EBITDA guidance of €30–50m confirmed 23
FY2025 revenue guidance revised down to €760–800m from €840–880m; adjusted EBITDA guidance of €30–50m confirmed 23
2025-Q2 · Apr – Jun 2025
„We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth. JEB maintained its strong growth trajectory with first half revenues in excess of € 100 m, and the evolution of our strategic partnership with Sandoz is testament to its bright future as a scalable technology provider with a more capital-efficient model. Our base business in D&PD continues to face soft demand, but we see strong progress in core collaborations and are systematically expanding our platform technologies, such as our Molecular Patient Database. I am confident that our unrelenting focus on technology and science leadership will continue to drive tangible impact in the future“ – Dr Christian Wojczewski, Chief Executive Officer 26
Revenue decelerating 2025-08-13
H1 2025 group revenues declined 5.0% to €371.2m; Discovery & Preclinical Development down 11.0% due to soft demand from small biotech companies, partially offset by Just – Evotec Biologics growth of 16% 24
H1 2025 group revenues declined 5.0% to €371.2m; Discovery & Preclinical Development down 11.0% due to soft demand from small biotech companies, partially offset by Just – Evotec Biologics growth of 16% 24
Divestiture 2025-08-13
Non-binding agreement signed to sell Just – Evotec Biologics EU including Toulouse J.POD facility to Sandoz AG for approximately US$300m plus technology licence and future milestone/royalty payments, closing expected in Q4 26
Non-binding agreement signed to sell Just – Evotec Biologics EU including Toulouse J.POD facility to Sandoz AG for approximately US$300m plus technology licence and future milestone/royalty payments, closing expected in Q4 26
Strategic pivot 2025-06-30
Segment renamed from 'Shared R&D' to 'Discovery & Preclinical Development', reflecting strategic refocus on core drug discovery strengths; D&PD recovery expected as early as 2026 24
Segment renamed from 'Shared R&D' to 'Discovery & Preclinical Development', reflecting strategic refocus on core drug discovery strengths; D&PD recovery expected as early as 2026 24
2025-Q1 · Jan – Mar 2025
„With € 200 m of revenues we ended Q1 2025 slightly ahead of our expectation, despite a soft drug discovery market environment. Just – Evotec Biologics has again delivered strong growth against an already outstanding Q1 2024 and will further leverage its capabilities as a scalable technology provider. We are on track to refocusing Evotec on its core strengths, preparing for sustainable profitable growth. I am deeply convinced about our ability to benefit from the opportunities that lie ahead of us. We are writing the next chapter of Evotec's success story as a drug discovery pioneer.“ – Dr Christian Wojczewski, Chief Executive Officer 27
„Evotec's ambitious new direction paves the way for sustainable profitable long-term growth. We are refocusing Evotec on its core strengths: technology and science leadership, where we deliver maximum impact for customers and patients. By combining cutting-edge technology platforms, disruptive science, and AI-driven innovation, we are accelerating the journey from concept to cure with our partners. We delivered on 2024 financial guidance, and I am excited about the opportunities that lie ahead of us. Together with our talented teams, we are writing the next chapter of Evotec's success story as a drug discovery pioneer.“ – Dr Christian Wojczewski, Chief Executive Officer 19
Strategic pivot 2025-05-06
Strategic protein degradation partnership with Bristol Myers Squibb expanded; combined US$75m in performance-based and program-based payments triggered 27
Strategic protein degradation partnership with Bristol Myers Squibb expanded; combined US$75m in performance-based and program-based payments triggered 27
Guidance initiated 2025-04-17
FY2025 guidance initiated: group revenues €840–880m, adjusted EBITDA €30–50m 19
FY2025 guidance initiated: group revenues €840–880m, adjusted EBITDA €30–50m 19
Strategic pivot 2025-04-17
Strategic review completed; company refocusing on drug discovery and pre-clinical development with simplified two-pillar business model, asset portfolio streamlined by approximately 30% 19
Strategic review completed; company refocusing on drug discovery and pre-clinical development with simplified two-pillar business model, asset portfolio streamlined by approximately 30% 19
2024 · 16 events
2024-Q4 · Oct – Dec 2024
„Evotec is unleashing innovation to develop life-changing medicines. We are pioneers in drug discovery and development, leveraging cutting-edge technology, disruptive science, and AI-driven innovation.“ – Dr Christian Wojczewski, Chief Executive Officer 20
Operating income turned positive 2025-04-17
Operating income turned positive for the first time after 6 negative periods (-26.5 to +6.8 EURm). 19
Operating income turned positive for the first time after 6 negative periods (-26.5 to +6.8 EURm). 19
Cash flow inflection 2025-04-17
Operating cash flow reached 74.2 EURm vs 19.9 EURm in 2023-Q4 (×3.7). 19
Operating cash flow reached 74.2 EURm vs 19.9 EURm in 2023-Q4 (×3.7). 19
Operating cash flow turned positive 2025-04-17
Operating cash flow turned positive on a half-year basis (2024-H1: -98.6 to 2024-H2: +116.8 EURm, aggregated from reported quarters where needed). 19
Operating cash flow turned positive on a half-year basis (2024-H1: -98.6 to 2024-H2: +116.8 EURm, aggregated from reported quarters where needed). 19
Guidance initiated 2025-04-14
Management guidance for 2025 projects Group revenues of €840-880m and Adjusted Group EBITDA of €30-50m 20
Management guidance for 2025 projects Group revenues of €840-880m and Adjusted Group EBITDA of €30-50m 20
Acquisition 2025-04-14
Halozyme Therapeutics made a non-binding acquisition proposal in November 2024 which was unexpectedly withdrawn within a week 20
Halozyme Therapeutics made a non-binding acquisition proposal in November 2024 which was unexpectedly withdrawn within a week 20
Divestiture 2025-04-14
Divested holdings in Recursion Pharmaceuticals for €69.4m cash inflow; Evotec DS Germany sold for €1 in December 2024 20
Divested holdings in Recursion Pharmaceuticals for €69.4m cash inflow; Evotec DS Germany sold for €1 in December 2024 20
2024-Q3 · Jul – Sep 2024
Guidance confirmed 2024-06-30
Full-year 2024 guidance confirmed: revenues €790-820m, adjusted EBITDA €15-35m, R&D expenditures €50-60m 14
Full-year 2024 guidance confirmed: revenues €790-820m, adjusted EBITDA €15-35m, R&D expenditures €50-60m 14
New market 2024-06-30
Grand opening of J.POD biologics facility in Toulouse, France on 20 September 2024 14
Grand opening of J.POD biologics facility in Toulouse, France on 20 September 2024 14
Divestiture 2024-06-30
Share Purchase Agreement signed on 2 November 2024 for sale of Evotec DS; operations reclassified as held for sale as of 30 September 2024 14
Share Purchase Agreement signed on 2 November 2024 for sale of Evotec DS; operations reclassified as held for sale as of 30 September 2024 14
2024-Q2 · Apr – Jun 2024
Adjusted result turned negative 2024-06-30
One-off reorganisation costs of €68m recognised in H1 2024; H1 adjusted Group EBITDA turned negative to €(0.5)m from €33.9m in H1 2023 13
One-off reorganisation costs of €68m recognised in H1 2024; H1 adjusted Group EBITDA turned negative to €(0.5)m from €33.9m in H1 2023 13
Margin compressing 2024-06-30
H1 gross margin declined to 12.9% from 25.9%, driven by lower top-line performance, high fixed-cost base, under-utilisation in Shared R&D and increased labour and material costs in Just-Evotec Biologics 13
H1 gross margin declined to 12.9% from 25.9%, driven by lower top-line performance, high fixed-cost base, under-utilisation in Shared R&D and increased labour and material costs in Just-Evotec Biologics 13
Guidance cut 2024-06-30
FY2024 guidance revised: revenues now expected €790-820m (previously low to mid-single digit growth), adjusted EBITDA €15-35m (previously mid-double digit growth) 13
FY2024 guidance revised: revenues now expected €790-820m (previously low to mid-single digit growth), adjusted EBITDA €15-35m (previously mid-double digit growth) 13
2024-Q1 · Jan – Mar 2024
Revenue decelerating 2024-06-30
Group revenues decreased 2% to 208.7 million; Shared R&D declined 23% while Just-Evotec Biologics surged 383% to €53.5m 12
Group revenues decreased 2% to 208.7 million; Shared R&D declined 23% while Just-Evotec Biologics surged 383% to €53.5m 12
Strategic pivot 2024-06-30
Priority reset announced: exit from gene therapy and Orth Austria site, headcount reduction of approximately 400 roles, and expected annualised EBITDA improvement greater than €40m starting H2 2024 12
Priority reset announced: exit from gene therapy and Orth Austria site, headcount reduction of approximately 400 roles, and expected annualised EBITDA improvement greater than €40m starting H2 2024 12
2023 · 9 events
2023-Q4 · Oct – Dec 2023
„I am immensely grateful to my colleagues within Evotec, who showed their absolute best during the recovery that followed.“ – Dr Mario Polywka, Chief Executive Officer 11
Operating cash flow turned positive 2025-04-17
Operating cash flow turned positive on a half-year basis (2023-H1: -5.6 to 2023-H2: +42.0 EURm, aggregated from reported quarters where needed). 19
Operating cash flow turned positive on a half-year basis (2023-H1: -5.6 to 2023-H2: +42.0 EURm, aggregated from reported quarters where needed). 19
New market 2024-04-22
EVT201 approved by the Chinese National Medical Products Administration as a novel insomnia treatment in December 2023 11
EVT201 approved by the Chinese National Medical Products Administration as a novel insomnia treatment in December 2023 11
Divestiture 2024-04-22
Sanofi partnership ended in November 2023 after more than five years, with capacities redeployed to fee-for-service business 11
Sanofi partnership ended in November 2023 after more than five years, with capacities redeployed to fee-for-service business 11
2023-Q3 · Jul – Sep 2023
„ALL ELEMENTS OF GUIDANCE CONFIRMED“ – Evotec 4
Revenue accelerating ◦ 2023-09-30
Just – Evotec Biologics contributed €74.1 million in 9M 2023 revenue versus €27.9 million in 9M 2022, with the biologics segment nearly tripling its revenues 4
Just – Evotec Biologics contributed €74.1 million in 9M 2023 revenue versus €27.9 million in 9M 2022, with the biologics segment nearly tripling its revenues 4
New market 2023-09-30
Launch of LAB eN² translational drug discovery accelerator with Novo Nordisk and academic institutions including Harvard, Yale, and Beth Israel Deaconess Medical Center 4
Launch of LAB eN² translational drug discovery accelerator with Novo Nordisk and academic institutions including Harvard, Yale, and Beth Israel Deaconess Medical Center 4
2023-Q2 · Apr – Jun 2023
Guidance cut 2023-08-29
FY 2023 guidance reduced to revenue €750–790 million and adjusted EBITDA €60–80 million, reflecting approximately €70 million in missed net revenues attributed to the cyber-attack 3
FY 2023 guidance reduced to revenue €750–790 million and adjusted EBITDA €60–80 million, reflecting approximately €70 million in missed net revenues attributed to the cyber-attack 3
New market 2023-05-15
Just – Evotec Biologics entered multi-year technology partnership with Sandoz for biosimilar development and commercial manufacturing, with upfront payments and future payments of up to US$640 million 1
Just – Evotec Biologics entered multi-year technology partnership with Sandoz for biosimilar development and commercial manufacturing, with upfront payments and future payments of up to US$640 million 1
2023-Q1 · Jan – Mar 2023
New market 2023-05-15
New strategic collaboration with Janssen Biotech for first-in-class immune-based oncology therapies, with US$50 million upfront payment and total deal potential of up to US$4 billion 1
New strategic collaboration with Janssen Biotech for first-in-class immune-based oncology therapies, with US$50 million upfront payment and total deal potential of up to US$4 billion 1
Advertisement
Key Figures (€m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Revenue (€m) · annual basis, as reported
Net income (€m) · annual basis, as reported
EPS (€) · annual basis, as reported
Operating cash flow (€m) · annual basis, as reported
Revenue (€m) · quarterly basis, as reported
Net income (€m) · quarterly basis, as reported
EPS (€) · quarterly basis, as reported
Operating cash flow (€m) · quarterly basis, as reported
Cash (€m) · annual basis, as reported
Debt (€m) · annual basis, as reported
Net Debt (€m) · annual basis, as reported
Capex (€m) · annual basis, as reported
FCF (€m) · annual basis, as reported
D&A (€m) · annual basis, as reported
Cash (€m) · quarterly basis, as reported
Debt (€m) · quarterly basis, as reported
Net Debt (€m) · quarterly basis, as reported
Capex (€m) · quarterly basis, as reported
FCF (€m) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2022 is on record.
Fiscal years
Amounts in €m · EPS in € per share · as reported
| Period | Revenue | Op. income | Net income | EPS (€) | EBITDA (adj.) | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 788.4 | -56.2 | -103.5 | -0.58 | -12 | -9.2 | 131 |
| FY2024 | 797 | -142.5 | -196.1 | -1.11 | 9.9 | 18.2 | 131 |
| FY2023 | 781.4 | -47.5 | -83.9 | -0.47 | 66.4 | 36.4 | 131 |
Quarters
Amounts in €m · EPS in € per share · as reported
| Period | Published | Revenue | Op. income | Net income | EPS (€) | EBITDA (adj.) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-06-30 | 143.5~ | -113.3 | -46.6 | -0.26*≈ | 3.6 | -116.3 | 348.4 | 127.5 | 133 |
| 2026-Q1* | 2026-06-30 | 156.6 | -121.4 | -121.9 | -0.69≈ | -21.9 | -8.1 | 387.9 | -0.5 | 32 |
| 2025-Q4* | 2025-12-31 | 253.3 | 36.1 | 14.6 | 0.08*≈ | 4.8 | – | 418.5 | 30.2 | 131 |
| 2025-Q3* | 2025-06-30 | 163.9 | -44.5 | -43.1 | -0.24 | -15 | -87.8 | 179.3~ | 305.3~ | 125 |
| 2025-Q2* | 2025-06-30 | 171.2 | -27.8 | -43.5 | -0.24 | -5 | 7.1 | 267.8 | 180.9 | 24 |
| 2025-Q1* | 2025-05-06 | 200 | -20 | -31.6 | -0.18≈ | 3.1 | -50 | 285.4 | 193.3 | 124 |
| 2024-Q4* | 2025-04-17 | 221.2 | 6.8 | -40.8 | -0.23*≈ | 15.8 | – | 306.4 | 137.2 | 19 |
| 2024-Q3* | 2024-06-30 | 184.9 | -26.5 | -39.6 | -0.22 | -5.5 | 15.8 | 231.3 | 238.8 | 125 |
| 2024-Q2* | 2024-06-30 | 182.1 | -104.6 | -94.9 | -0.54 | -8.3 | -85.7 | 428.3~ | 45.2~ | 115 |
| 2024-Q1* | 2024-06-30 | 208.7 | -18.2 | -20.7 | -0.12≈ | 7.8 | -88.4 | 428.3 | 199.2 | 12 |
| 2023-Q4* | 2025-04-17 | 201.3 | -11.5 | -16.1 | -0.09*≈ | 16.1 | -43.4 | 510.9 | 115.3 | 19 |
| 2023-Q3* | 2024-06-30 | 196.3 | -12.2 | -39 | -0.22≈ | 16.3 | -23.9 | 499.4 | – | 116 |
| 2023-Q2* | 2023-06-30 | 170.3 | -36.3 | -14.9 | -0.08 | -0.4 | -67.1 | 459.8 | 74.4 | 112 |
| 2023-Q1* | 2023-08-29 | 213.6 | 12.5 | -13.9 | -0.08≈ | 34.3 | -42.5 | 412.9 | – | 3 |
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
The publication date of individual rows is a publisher placeholder (not the actual publication date).
Columns not reported in this reporting cadence are hidden: Op. income (adj.), EPS adj. (not reported in any source for these periods).
Advertisement
Balance Sheet & Cash Flow (€m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
Fiscal years
Amounts in €m · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2025-12-31 | 418.5 | 448.7 | 30.2 | 99.5 | -9.2 | 72.5 | -81.7 | 131 |
| FY2024 | 2025-04-14 | 306.4 | 443.5 | 137.2 | 101.6 | 18.2 | 117.5~ | -99.2~ | 131 |
| FY2023 | 2024-04-22 | 510.9 | 626.2 | 115.3 | 93 | 36.4 | 213.3 | -176.9 | 131 |
Quarters
Amounts in €m · as reported
| Period | Published | Cash | Debt | Net Debt | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-06-30 | 348.4 | 475.9 | 127.5 | -107.2 | 9.1 | -116.3 | 133 |
| 2026-Q1 | 2026-06-30 | 387.9 | 387.5 | -0.5 | -3.9 | 4.2 | -8.1 | 32 |
| 2025-Q4 | 2025-12-31 | 418.5 | 448.7 | 30.2 | 63.6 | 28.7 | – | 131 |
| 2025-Q3 | 2025-06-30 | 179.3~ | 484.6 | 305.3~ | -67.6 | 20.2 | -87.8 | 125 |
| 2025-Q2 | 2025-06-30 | 267.8 | 448.7 | 180.9 | 26.6 | 19.4 | 7.1 | 24 |
| 2025-Q1 | 2025-05-06 | 285.4 | 478.7 | 193.3 | -31.8 | 18.2 | -50 | 124 |
| 2024-Q4 | 2025-04-17 | 306.4 | 443.5 | 137.2 | 74.2 | 37.2~ | – | 19 |
| 2024-Q3 | 2024-06-30 | 231.3 | 470.1 | 238.8 | 42.6 | 26.8 | 15.8 | 125 |
| 2024-Q2 | 2024-06-30 | 428.3~ | 473.5 | 45.2~ | -50.4 | 35.3 | -85.7 | 115 |
| 2024-Q1 | 2024-06-30 | 428.3 | 627.6 | 199.2 | -48.2 | 40.2 | -88.4 | 12 |
| 2023-Q4 | 2025-04-17 | 510.9 | 626.2 | 115.3 | 19.9 | 63.4 | -43.4 | 19 |
| 2023-Q3 | 2024-06-30 | 499.4 | – | – | 22.1 | 45.9 | -23.9 | 116 |
| 2023-Q2 | 2023-06-30 | 459.8 | 534.1 | 74.4 | -6.2 | 60.9 | -67.1 | 112 |
| 2023-Q1 | 2023-08-29 | 412.9 | – | – | 0.6 | 43.1 | -42.5 | 3 |
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
The publication date of individual rows is a publisher placeholder (not the actual publication date).
Advertisement
Revenue by Type (as of 2026-Q2 · EURm · 3/5)#
Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.
| Segment | Since | Period | Basis | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|---|---|
| D&PD (Discovery & Preclinical Development) | 2025-H1 | 2026-H1 | 6M | 227.9 | -15.2% | 4.4% | 31 |
| Discovery & Preclinical Development | 2024-H1 | FY2025 | 12M | – | -13.5% | 9% | 29 |
| Shared R&D | 2023-Q1 | 2025-Q1 | 3M | 140.6 | -9% | 10.8% | 22 |
| EVT Execute | FY2022 | FY2023 | 12M? | 514.5 | – | – | 11 |
| EVT Innovate | FY2022 | FY2023 | 12M | 266.9 | – | – | 11 |
Advertisement
Products & M&A (15/40 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.
| Product/Line | Since | Status | Source |
|---|---|---|---|
| Odyssey Therapeutics AI collaboration in autoimmune and inflammatory diseases | 2026-08 | Launched | 31 |
| J.TRAIN turnkey continuous manufacturing | 2026-06 | Launched | 31 |
| Small molecule preclinical development candidate with Almirall dermatology | 2026-05 | Launched | 31 |
| Horizon Transformation Initiative | 2026-03 | Launched | 29 |
| BARDA project agreement for antibody biomanufacturing optimization | 2026-03 | Launched | 31 |
| Gates Foundation TB Grant (2x) | 2026-01 | Launched | 24 |
| Digital health and safety system deployment | 2026 | Launched | 29 |
| Toulouse France manufacturing facility | 2025-03 | Launched | 12 |
| South Korea Grant for Lung Disease Antibody Treatment | 2025-03 | Launched | 29 |
| New customers for long-term development and commercial manufacturing in Biologics | 2025-03 | Launched | 19 |
| Bristol Myers Squibb multi-year collaboration extension in neuroscience and targeted protein degradation | 2025-03 | Launched | 19 |
| Nomination of Preclinical Development Candidate with Esperion for Primary Sclerosing Cholangitis | 2025 | Launched | 23 |
| Innovation Board establishment | 2025 | Launched | 29 |
| IND Submission for Novel Oncology Therapy by Dewpoint Therapeutics | 2025 | Launched | 23 |
| Global Health & Safety Policy approval | 2025 | Launched | 29 |
| iPSC lighthouse building Hamburg | 2024 | Launched | 11 |
| iPSC centre in Hamburg | 2024 | Launched | 11 |
| BMS-986419/EVT8683 Phase II trial in ALS | 2024 | Launched | 4 |
| EVT201 approval in China | 2023-12 | Launched | 11 |
| 65LAB first BRIDGE partnership in Asia | 2023-10 | Launched | 4 |
| LAB eN² translational drug discovery accelerator | 2023-09 | Launched | 4 |
| Building 95 state-of-the-art biology facility opening | 2023-09 | Launched | 4 |
| EVT401 Phase I clinical trial | 2023-08 | Launched | 4 |
| Sernova Diabetes Phase I Initiation | 2023-06 | Launched | 3 |
| Kazia Oncology Phase I Data (EVT801) | 2023-06 | Launched | 3 |
| JingXin Phase III & Registration Trial (Insomnia EVT201) | 2023-06 | Launched | 3 |
| Exscientia Oncology Phase Ib/II Initiation (EXS21546) | 2023-06 | Launched | 3 |
| Chikungunya Virus Phase I Data (EVT894) | 2023-06 | Launched | 3 |
| Bayer kidney disease programme Phase I first patient dosed (2x) | 2023-06 | Launched | 10 |
| Bayer Phase I clinical study initiation for Alport syndrome treatment | 2023-06 | Launched | 11 |
| Bayer Phase I Kidney Disease Trial (2x) | 2023-06 | Launched | 5 |
| BMS CNS Phase I Data (EVT8683) | 2023-06 | Launched | 3 |
| Cyprotex US relocation to Framingham facility (2×) | 2023-04 | Launched | 5 |
| The Bill & Melinda Gates Foundation grant for tuberculosis drug discovery | 2023-03 | Launched | 1 |
| Scientific progress in BMS targeted protein degradation alliance | 2023-03 | Launched | 10 |
| Janssen cell therapy partnership | 2023-03 | Launched | 11 |
| BMS contract extensions | 2023-03 | Launched | 11 |
| J.POD US facility expansion | 2023 | Launched | 11 |
| J.POD Toulouse facility (10×) | 2023 | Launched | 20 |
Advertisement
M&A (75)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.
Acquisitions · 48Divestitures/exits · 24older: 1 (in the table)
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Tubulis acquisition by Gilead Sciences | 2026-05 | Completed | 31 |
| BARDA project agreement with Just-Evotec Biologics | 2026-03 | Announced | 32 |
| Gates Foundation AI-driven monoclonal antibody grant | 2026-01 | Completed | 32 |
| Sandoz Toulouse Site Transaction | 2025-12 | Completed | 29 |
| License Agreement with Sandoz for biosimilar portfolio | 2025-12 | Announced | 29 |
| Dark Blue Therapeutics Acquisition by Amgen (2×) | 2025-12 | Completed | 29 |
| Share capital increase authorization | 2025-06 | Completed | 11 |
| NURTuRE-AKI consortium membership | 2025-06 | Completed | 26 |
| Gates Foundation grant for tuberculosis treatment development | 2025-06 | Completed | 26 |
| Conditional capital authorization | 2025-06 | Completed | 11 |
| BMS Neuroscience Collaboration (2×) | 2025-06 | Completed | 24 |
| Korean government grant for novel antibody-based treatments for lung diseases | 2025-03 | Completed | 22 |
| CFO succession: Paul Hitchin replaces Laetitia Rouxel | 2025-03 | Completed | 22 |
| Bristol Myers Squibb strategic partnership in molecular glue degraders | 2025-03 | Completed | 27 |
| Halozyme Therapeutics non-binding acquisition proposal | 2024-11 | Completed | 20 |
| Novo Nordisk technology development partnership for next-generation cell therapies (2x) | 2024-09 | Completed | 19 |
| Expansion of proteomics partnership with Bristol Myers Squibb based on molecular glue degraders pipeline | 2024-09 | Completed | 14 |
| Collaboration with X-Chem to access DNA-encoded library to expand hit-finding options | 2024-09 | Completed | 14 |
| 65LAB and Duke-NUS award US$ 1.85 million to combat chronic inflammation | 2024-09 | Completed | 14 |
| Strategic partnership with Variant Bio for fibrosis treatments | 2024-03 | Completed | 12 |
| Strategic partnership with Owkin | 2024-03 | Completed | 12 |
| Framework with Claris Ventures to accelerate portfolio companies | 2024-03 | Completed | 12 |
| Expanded Just-Evotec Biologics manufacturing agreement with ABL | 2024-03 | Announced | 12 |
| Bayer collaboration for precision cardiology | 2024-03 | Completed | 12 |
| Agreement with Colitis Foundation for IBD therapies | 2024-03 | Announced | 12 |
| Strategic research alliance with Pfizer in metabolic and infectious diseases | 2024 | Completed | 20 |
| Precision medicine partnership in cardiology with Bayer | 2024 | Completed | 20 |
| New collaboration with Novo Nordisk in Cell Therapy | 2024 | Completed | 20 |
| Multi-year master research collaboration with Pfizer (4x) | 2024 | Completed | 19 |
| Just - Evotec Biologics investments | 2024 | Completed | 20 |
| BMS collaboration extension into new disease area | 2024 | Completed | 20 |
| U.S. Department of Defense monoclonal antibody contract | 2023-07 | Completed | 5 |
| Nephtera acquisition of remaining 50% share | 2023-07 | Completed | 10 |
| DOD contract for rapid monoclonal antibody development against orthopoxviruses | 2023-07 | Completed | 10 |
| Sernova iPSC-based Diabetes Therapy Investment | 2023-06 | Completed | 3 |
| Open Philanthropy grant for RNA-targeting platform | 2023-06 | Completed | 5 |
| Janssen collaboration | 2023-06 | Completed | 7 |
| BMS Protein Degradation Partnership (4×) | 2023-06 | Completed | 24 |
| Sandoz technology partnership (9×) | 2023-05 | Completed | 10 |
| Just – Evotec Biologics partnership with Sandoz for biosimilars | 2023-05 | Completed | 1 |
| Long-term alliance with Sandoz in biosimilars | 2023-03 | Completed | 2 |
| Bristol Myers Squibb neuroscience partnership expansion (11×) | 2023-03 | Completed | 31 |
| BMS Neurodegeneration Partnership Extension (4×) | 2023-03 | Completed | 10 |
| Related Sciences drug discovery agreement extended through 2030 (3×) | 2023-02 | Announced | 5 |
| Janssen Immune-based Oncology Collaboration (6×) | 2023-01 | Completed | 5 |
| NephThera GmbH acquisition | 2023 | Completed | 11 |
| Dewpoint Therapeutics partnership for biomolecular condensates | 2023 | Completed | 11 |
| EIB financing EUR 150 m | 2022 | Completed | 20 |
| U.S. Department of Defense agreement | – | Announced | 7 |
| Sandoz agreement | – | Announced | 7 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Carrick Therapeutics Divestiture | 2025-10 | Divested | 29 |
| Sale of Just-Evotec Biologics EU and J.POD manufacturing facility | 2025-07 | Divested | 26 |
| Sale of JUST EU (5×) | 2025-07 | Divested | 31 |
| Cologne Site Closure | 2025-02 | Divested | 29 |
| Toulouse site of Just Evotec Biologics sold to Sandoz | 2025 | Divested | 29 |
| Divestiture of holdings in Recursion Pharmaceuticals | 2024-12 | Divested | 20 |
| Discontinuation and sale of Halle/Westphalia site to Monacum Partners | 2024-12 | Divested | 20 |
| Divestiture of Evotec DS business activities | 2024-11 | Divested | 14 |
| Reduction of physical footprint through surrendering of certain lease agreements | 2024-09 | Divested | 14 |
| Exit of gene therapy and closure of operations in Orth, Austria and Chemistry activities in Marcy (Lyon) | 2024-09 | Divested | 14 |
| Halle/Westphalia Germany operations no longer considered core activity | 2024-06 | Divested | 13 |
| Gene therapy exit and closure of Orth Austria site | 2024-06 | Divested | 13 |
| Chemistry activities closure in Marcy (Lyon) | 2024-06 | Divested | 13 |
| Strategic exit of gene therapy | 2024-03 | Divested | 12 |
| Closure of Orth Austria site | 2024-03 | Divested | 12 |
| Recursion Pharmaceutical shares sale | 2024 | Divested | 20 |
| Rationalization of Real Estate Footprint in Germany (Cologne, Gottingen, Hamburg facility closures) | 2024 | Divested | 20 |
| Exit of gene therapy activities in Orth, Austria | 2024 | Divested | 20 |
| Exit of Chemistry activities in Marcy/Lyon, France | 2024 | Divested | 20 |
| Evotec DS Germany GmbH sale (3x) | 2024 | Divested | 20 |
| Discontinuation of Gene Therapy operation in Orth (Austria) | 2024 | Divested | 20 |
| Closure of Marcy site (France) | 2024 | Divested | 20 |
| Tucana Biosciences Inc share sale | 2023-12 | Divested | 11 |
| Bayer discontinuation of women's health clinical assets; rights return to Evotec | 2023-05 | Divested | 1 |
Terminated / withdrawn
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Sandoz Agreement for Just-Evotec Biologics Toulouse Facility | 2025-11 | Terminated | 23 |
Advertisement
Reported KPIs (as disclosed) (532)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.
Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| – | 2026-H1 | Total Liquidity | 465.6 m | 31 |
| – | 2026-H1 | Gross margin JEB | (18.3) % | 31 |
| – | 2026-H1 | Gross margin D&PD | 4.4 % | 31 |
| – | 2026-H1 | Gross margin | (1.0) % | 31 |
| – | 2026-H1 | Equity ratio | 42.3 % | 31 |
| – | 2026-Q1 | Just Evotec Biologics revenue | 36,844 (EUR in k€) | 32 |
| – | 2026-Q1 | Just Evotec Biologics gross margin | (24) % | 32 |
| – | 2026-Q1 | Just Evotec Biologics adjusted EBITDA | (12,051) | 32 |
| – | 2026-Q1 | Group gross margin | (1) % | 32 |
| – | 2026-Q1 | Equity ratio | 42.7 % | 32 |
| – | 2026-Q1 | D&PD revenue | 119,800 (EUR in k€) | 32 |
| – | 2026-Q1 | D&PD gross margin | 6 % | 32 |
| – | 2026-Q1 | D&PD adjusted EBITDA | (9,800) | 32 |
| 2026-03-31 | FY2025 | water consumption intensity 2025 | 0.0005 | 29 |
| 2026-03-31 | FY2025 | water consumption in water risk areas 2025 | 54,240 | 29 |
| 2026-03-31 | FY2025 | water consumption 2025 | 368,504 | 29 |
| 2026-03-31 | FY2025 | waste not recovered percentage 2025 | 46% | 29 |
| 2026-03-31 | FY2025 | waste generated 2025 | 3,382 | 29 |
| 2026-03-31 | FY2025 | waste directed to recovery non-hazardous 2025 | 977 | 29 |
| 2026-03-31 | FY2025 | waste directed to recovery hazardous 2025 | 835 | 29 |
| 2026-03-31 | FY2025 | waste directed to disposal non-hazardous 2025 | 484 | 29 |
| 2026-03-31 | FY2025 | waste directed to disposal hazardous 2025 | 1,085 | 29 |
| 2026-03-31 | FY2025 | wage taxes | 5,692 | 29 |
| 2026-03-31 | FY2025 | variable interest-bearing loans | 5% | 29 |
| 2026-03-31 | FY2025 | USD liquid assets | 21% | 29 |
| 2026-03-31 | FY2025 | total gross GHG emissions market-based 2025 | 139,870 | 29 |
| 2026-03-31 | FY2025 | total gross GHG emissions location-based 2025 | 155,408 | 29 |
| 2026-03-31 | FY2025 | total energy consumption 2025 | 166,578 | 29 |
| 2026-03-31 | FY2025 | suppliers with science-based targets target 2027 | 80% | 29 |
| 2026-03-31 | FY2025 | suppliers with science-based targets 2025 | 43% | 29 |
| 2026-03-31 | FY2025 | social security liabilities | 5,645 | 29 |
| 2026-03-31 | FY2025 | significant harm events | 0 | 29 |
| 2026-03-31 | FY2025 | short-term investments | 57,873 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | right-of-use assets | 154,852 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | revenue from three customers | 43% | 29 |
| 2026-03-31 | FY2025 | reportable work-related injuries | 16 | 29 |
| 2026-03-31 | FY2025 | renewable energy of total sources 2025 | 52% | 29 |
| 2026-03-31 | FY2025 | renewable electricity sourcing target 2026 | 100% | 29 |
| 2026-03-31 | FY2025 | renewable electricity sourcing 2021 | 25% | 29 |
| 2026-03-31 | FY2025 | renewable electricity percentage 2025 | 99.9% | 29 |
| 2026-03-31 | FY2025 | R&D tax credits | 41.6 m | 29 |
| 2026-03-31 | FY2025 | radioactive waste 2025 | 0.79 | 29 |
| 2026-03-31 | FY2025 | purchased goods and services Scope 3 emissions intensity 2025 | 0.231 | 29 |
| 2026-03-31 | FY2025 | property, plant & equipment net book value | 399,774 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | other long-term investments | 42,640 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | non-hazardous waste 2025 | 1,461 | 29 |
| 2026-03-31 | FY2025 | net zero target year | 2045 | 29 |
| 2026-03-31 | FY2025 | LTISR | 0.17 | 29 |
| 2026-03-31 | FY2025 | LTIFR | 1.1 | 29 |
| 2026-03-31 | FY2025 | lost time injuries | 11 | 29 |
| 2026-03-31 | FY2025 | lease obligations total | 171,286 | 29 |
| 2026-03-31 | FY2025 | lease obligations non-current | 149,104 | 29 |
| 2026-03-31 | FY2025 | lease obligations current | 22,182 | 29 |
| 2026-03-31 | FY2025 | hazardous waste 2025 | 1,921 | 29 |
| 2026-03-31 | FY2025 | gross Scope 3 GHG emissions 2025 | 126,108 | 29 |
| 2026-03-31 | FY2025 | gross Scope 2 market-based GHG emissions 2025 | 2,583 | 29 |
| 2026-03-31 | FY2025 | gross Scope 2 location-based GHG emissions 2025 | 18,121 | 29 |
| 2026-03-31 | FY2025 | gross Scope 1 GHG emissions 2025 | 11,179 | 29 |
| 2026-03-31 | FY2025 | fatalities | 0 | 29 |
| 2026-03-31 | FY2025 | EUR liquidity held | 73% | 29 |
| 2026-03-31 | FY2025 | energy intensity reduction since 2021 | 30% | 29 |
| 2026-03-31 | FY2025 | energy intensity 2025 | 211 | 29 |
| 2026-03-31 | FY2025 | days lost from work-related injuries | 170 | 29 |
| 2026-03-31 | FY2025 | customer alliances over 1M | 74 | 29 |
| 2026-03-31 | FY2025 | current deferred income | 11,570 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | cash and equivalents | 476.4 m | 29 |
| 2026-03-31 | FY2025 | Unrealized FX Loss 2024 | € (4.1) m | 29 |
| 2026-03-31 | FY2025 | Unrealized FX Gain | € 4.9 m | 29 |
| 2026-03-31 | FY2025 | Treasury Shares 2024 | 167,415 | 29 |
| 2026-03-31 | FY2025 | Treasury Shares | 319,507 | 29 |
| 2026-03-31 | FY2025 | Total Revenue Group | € 788.373 m | 29 |
| 2026-03-31 | FY2025 | Total Equity Evotec SE 2024 | € 839.4 m | 29 |
| 2026-03-31 | FY2025 | Total Equity | € 805.5 m | 29 |
| 2026-03-31 | FY2025 | Total Awards Granted for Future Exercise 2024 | 2,645,773 | 29 |
| 2026-03-31 | FY2025 | Total Awards Granted for Future Exercise | 3,929,737 | 29 |
| 2026-03-31 | FY2025 | Total Assets Evotec SE 2024 | € 1,290.3 m | 29 |
| 2026-03-31 | FY2025 | Total Assets Evotec SE | € 1,231.6 m | 29 |
| 2026-03-31 | FY2025 | Total Assets 2024 | € 1,912.5 m | 29 |
| 2026-03-31 | FY2025 | Total Assets | € 1,713.9 m | 29 |
| 2026-03-31 | FY2025 | Top 10 customers contribution to total revenues | 61% | 29 |
| 2026-03-31 | FY2025 | Third party revenues Evotec SE 2024 | € 9.4 m | 29 |
| 2026-03-31 | FY2025 | Third party revenues Evotec SE | € 0.6 m | 29 |
| 2026-03-31 | FY2025 | Stockholders Equity 2024 | € 952.5 m | 29 |
| 2026-03-31 | FY2025 | Stockholders Equity | € 813.7 m | 29 |
| 2026-03-31 | FY2025 | Shares Repurchased | 290,000 | 29 |
| 2026-03-31 | FY2025 | Share Repurchase Price | €5.3711 | 29 |
| 2026-03-31 | FY2025 | Share Performance Awards Granted 2024 | 117,292 | 29 |
| 2026-03-31 | FY2025 | Share Performance Awards Granted | 445,702 | 29 |
| 2026-03-31 | FY2025 | Share Capital 2024 | € 177.6 m | 29 |
| 2026-03-31 | FY2025 | Share Capital | € 177.8 m | 29 |
| 2026-03-31 | FY2025 | Share Buyback Volume | € 1.5 m | 29 |
| 2026-03-31 | FY2025 | SG&A cost ratio | 22% | 29 |
| 2026-03-31 | FY2025 | SG&A as Percentage of Revenue JEB 2024 | 15.8% | 29 |
| 2026-03-31 | FY2025 | SG&A as Percentage of Revenue JEB | 16.5% | 29 |
| 2026-03-31 | FY2025 | SG&A Expenses JEB 2024 | € (29.3) m | 29 |
| 2026-03-31 | FY2025 | SG&A Expenses JEB | € (42.7) m | 29 |
| 2026-03-31 | FY2025 | SG&A Expenses DPD 2024 | € (158.9) m | 29 |
| 2026-03-31 | FY2025 | SG&A Expenses DPD | € (133.2) m | 29 |
| 2026-03-31 | FY2025 | Revenue USA Percentage | 56% | 29 |
| 2026-03-31 | FY2025 | Revenue Rest of World Percentage | 10% | 29 |
| 2026-03-31 | FY2025 | Revenue Europe Percentage | 34% | 29 |
| 2026-03-31 | FY2025 | Restricted Cash 2024 | € 12.9 m | 29 |
| 2026-03-31 | FY2025 | Restricted Cash | € 16.7 m | 29 |
| 2026-03-31 | FY2025 | Repeat business | 90% | 29 |
| 2026-03-31 | FY2025 | Repayment of Lease Obligations 2024 | € (24.1) m | 29 |
| 2026-03-31 | FY2025 | Repayment of Lease Obligations | € (23.6) m | 29 |
| 2026-03-31 | FY2025 | Repayment of Bank Loans 2024 | € (128.8) m | 29 |
| 2026-03-31 | FY2025 | Repayment of Bank Loans | € (49.7) m | 29 |
| 2026-03-31 | FY2025 | Reorganization Costs DPD 2024 | € (54.2) m | 29 |
| 2026-03-31 | FY2025 | Reorganization Costs DPD | € 0.6 m | 29 |
| 2026-03-31 | FY2025 | Renewable Electricity Consumption 2024 | 66% | 29 |
| 2026-03-31 | FY2025 | Renewable Electricity Consumption | 99.9% | 29 |
| 2026-03-31 | FY2025 | Realized FX Gain 2024 | € 1.9 m | 29 |
| 2026-03-31 | FY2025 | Realized FX Gain | € 6.7 m | 29 |
| 2026-03-31 | FY2025 | R&D cost ratio | 5% | 29 |
| 2026-03-31 | FY2025 | R&D Expenses DPD 2024 | € (51.1) m | 29 |
| 2026-03-31 | FY2025 | R&D Expenses DPD | € (37.5) m | 29 |
| 2026-03-31 | FY2025 | Property, Plant & Equipment 2024 | € 823.9 m | 29 |
| 2026-03-31 | FY2025 | Property, Plant & Equipment | € 554.6 m | 29 |
| 2026-03-31 | FY2025 | Proceeds from Sale of Just EU | € 222.6 m | 29 |
| 2026-03-31 | FY2025 | Proceeds from Bank Loans 2024 | € 0.9 m | 29 |
| 2026-03-31 | FY2025 | Proceeds from Bank Loans | € 44.0 m | 29 |
| 2026-03-31 | FY2025 | Personnel Cost | 456,536 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | Owned Assets 2024 | € 686.4 m | 29 |
| 2026-03-31 | FY2025 | Owned Assets | € 399.8 m | 29 |
| 2026-03-31 | FY2025 | Customers contributing more than EUR 1m to revenue | 74 | 29 |
| 2026-03-31 | FY2025 | Number of Customers | 735 | 29 |
| 2026-03-31 | FY2025 | Non-Current Loan Liabilities 2024 | € 260.4 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Loan Liabilities | € 194.9 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Lease Obligations 2024 | € 132.3 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Lease Obligations | € 149.1 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Financial Liabilities 2024 | € 392.7 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Financial Liabilities | € 344.0 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Deferred Income 2024 | € 30.6 m | 29 |
| 2026-03-31 | FY2025 | Non-Current Deferred Income | € 8.3 m | 29 |
| 2026-03-31 | FY2025 | Non-Cash Charges 2024 | € 206.4 m | 29 |
| 2026-03-31 | FY2025 | Non-Cash Charges | € 140.4 m | 29 |
| 2026-03-31 | FY2025 | Net Debt Leverage Ratio 2024 | 1.9x | 29 |
| 2026-03-31 | FY2025 | Net Debt Leverage Ratio | -0.7x | 29 |
| 2026-03-31 | FY2025 | Net Cash Inflow from Sale of Investments 2024 | € 35.7 m | 29 |
| 2026-03-31 | FY2025 | Net Cash Inflow from Sale of Investments | € 32.0 m | 29 |
| 2026-03-31 | FY2025 | Maximum Bearer Shares from SPAs 2024 | 234,584 | 29 |
| 2026-03-31 | FY2025 | Maximum Bearer Shares from SPAs | 891,404 | 29 |
| 2026-03-31 | FY2025 | Management Board Women | 1 | 29 |
| 2026-03-31 | FY2025 | Management Board Non-German | 2 | 29 |
| 2026-03-31 | FY2025 | Management Board Men | 3 | 29 |
| 2026-03-31 | FY2025 | Management Board Members | 4 | 29 |
| 2026-03-31 | FY2025 | Liquidity at Year End 2024 | 396,800 | 29 |
| 2026-03-31 | FY2025 | Liquidity at Year End | 476,390 | 29 |
| 2026-03-31 | FY2025 | Liquidity Evotec SE 2024 | € 150.3 m | 29 |
| 2026-03-31 | FY2025 | Liquidity Evotec SE | € 167.3 m | 29 |
| 2026-03-31 | FY2025 | Liquidity 2024 | € 396.8 m | 29 |
| 2026-03-31 | FY2025 | Liquidity | € 476.4 m | 29 |
| 2026-03-31 | FY2025 | Leased Assets 2024 | € 137.5 m | 29 |
| 2026-03-31 | FY2025 | Leased Assets | € 154.9 m | 29 |
| 2026-03-31 | FY2025 | Investments 2024 | 90,413 (EUR in €k) | 29 |
| 2026-03-31 | FY2025 | Investments | 57,873 (EUR in €k) | 29 |
| 2026-03-31 | FY2025 | Intercompany revenues Evotec SE 2024 | € 124.1 m | 29 |
| 2026-03-31 | FY2025 | Intercompany revenues Evotec SE | € 108.6 m | 29 |
| 2026-03-31 | FY2025 | Intercompany recharges Evotec SE 2024 | € 46.0 m | 29 |
| 2026-03-31 | FY2025 | Intercompany recharges Evotec SE | € 29.6 m | 29 |
| 2026-03-31 | FY2025 | Income Tax Expenses 2024 | € 2.1 m | 29 |
| 2026-03-31 | FY2025 | Income Tax Expenses | € 16.8 m | 29 |
| 2026-03-31 | FY2025 | Gross margin | 14.5% | 29 |
| 2026-03-31 | FY2025 | Gross Margin JEB 2024 | 7.3% | 29 |
| 2026-03-31 | FY2025 | Gross Margin JEB | 26.0% | 29 |
| 2026-03-31 | FY2025 | Gross Margin DPD 2024 | 16.7% | 29 |
| 2026-03-31 | FY2025 | Gross Margin DPD | 8.8% | 29 |
| 2026-03-31 | FY2025 | GHG intensity market based 2025 | 0.18 | 29 |
| 2026-03-31 | FY2025 | GHG intensity location based 2025 | 0.20 | 29 |
| 2026-03-31 | FY2025 | GHG emissions Scope 3 near term reduction target | 72% | 29 |
| 2026-03-31 | FY2025 | GHG emissions Scope 3 long term reduction target | 97% | 29 |
| 2026-03-31 | FY2025 | GHG emissions Scope 1 near term reduction target | 50.4% | 29 |
| 2026-03-31 | FY2025 | GHG emissions Scope 1 long term reduction target | 95% | 29 |
| 2026-03-31 | FY2025 | GBP EUR Average Rate 2024 | € 0.8466 | 29 |
| 2026-03-31 | FY2025 | GBP EUR Average Rate | € 0.8568 | 29 |
| 2026-03-31 | FY2025 | Future Payment Obligations 2024 | € 95.9 m | 29 |
| 2026-03-31 | FY2025 | Future Payment Obligations | € 112.3 m | 29 |
| 2026-03-31 | FY2025 | Free float | 83.57% | 29 |
| 2026-03-31 | FY2025 | Forward Rate Agreements USD GBP | € 29.6 m | 29 |
| 2026-03-31 | FY2025 | Forward Rate Agreements USD EUR | € 94.7 m | 29 |
| 2026-03-31 | FY2025 | Follow on Investments in Portfolio | € (14.0) m | 29 |
| 2026-03-31 | FY2025 | Fixed Interest Rate Bank Loans | 95% | 29 |
| 2026-03-31 | FY2025 | Exchange Rate Impact on Cash 2024 | € 9.9 m | 29 |
| 2026-03-31 | FY2025 | Exchange Rate Impact on Cash | € (12.7) m | 29 |
| 2026-03-31 | FY2025 | Equity ratio | 47.5 % | 29 |
| 2026-03-31 | FY2025 | Equity attributable to Shareholders | 813,704 | 29 |
| 2026-03-31 | FY2025 | Equity Ratio Evotec SE 2024 | 65.1% | 29 |
| 2026-03-31 | FY2025 | Equity Ratio Evotec SE | 65.4% | 29 |
| 2026-03-31 | FY2025 | Equity Ratio 2024 | 50% | 29 |
| 2026-03-31 | FY2025 | Equity Ratio | 47% | 29 |
| 2026-03-31 | FY2025 | EUR USD Average Rate 2024 | USD 1.0824 | 29 |
| 2026-03-31 | FY2025 | EUR USD Average Rate | USD 1.13 | 29 |
| 2026-03-31 | FY2025 | EBITDA | 41,145 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | Divestment Dark Blue Therapeutics | € (11.3) m | 29 |
| 2026-03-31 | FY2025 | Derivative Financial Instruments 2024 | € 105.8 m | 29 |
| 2026-03-31 | FY2025 | Derivative Financial Instruments | € 134.7 m | 29 |
| 2026-03-31 | FY2025 | Depreciation and Amortization 2024 | € 101.6 m | 29 |
| 2026-03-31 | FY2025 | Depreciation and Amortization | € 99.5 m | 29 |
| 2026-03-31 | FY2025 | Customers contributing more than €1m to revenue | 74 (EUR millions) | 29 |
| 2026-03-31 | FY2025 | Customer Retention | 90% | 29 |
| 2026-03-31 | FY2025 | Current Loan Liabilities 2024 | € 27.1 m | 29 |
| 2026-03-31 | FY2025 | Current Loan Liabilities | € 81.5 m | 29 |
| 2026-03-31 | FY2025 | Current Lease Obligations 2024 | € 19.6 m | 29 |
| 2026-03-31 | FY2025 | Current Lease Obligations | € 22.2 m | 29 |
| 2026-03-31 | FY2025 | Current Financial Liabilities 2024 | € 50.8 m | 29 |
| 2026-03-31 | FY2025 | Current Financial Liabilities | € 104.7 m | 29 |
| 2026-03-31 | FY2025 | Cost of Revenue JEB 2024 | € (173.1) m | 29 |
| 2026-03-31 | FY2025 | Cost of Revenue JEB | € (192.2) m | 29 |
| 2026-03-31 | FY2025 | Cost of Revenue DPD 2024 | € (509.4) m | 29 |
| 2026-03-31 | FY2025 | Cost of Revenue DPD | € (482.5) m | 29 |
| 2026-03-31 | FY2025 | Changes in Working Capital 2024 | € (68.2) m | 29 |
| 2026-03-31 | FY2025 | Changes in Working Capital | € (60.8) m | 29 |
| 2026-03-31 | FY2025 | Balance Sheet Total | 1,713,945 | 29 |
| 2026-03-31 | FY2025 | Awards as Percentage of Issued Shares 2024 | 1.5% | 29 |
| 2026-03-31 | FY2025 | Awards as Percentage of Issued Shares | 2.2% | 29 |
| 2026-03-31 | FY2025 | Adjusted Group EBITDA | 41.1 (EUR in k€) | 29 |
| 2026-03-31 | FY2025 | Additional Paid-in Capital 2024 | € 1,454.7 m | 29 |
| 2026-03-31 | FY2025 | Additional Paid-in Capital | € 1,458.5 m | 29 |
| – | 2025-Q3 | Total Liquidity | 237.3 m | 23 |
| – | 2025-Q3 | Total D&PD revenues decrease | (12.3)% | 23 |
| – | 2025-Q3 | Non-Sandoz / non-DoD business growth (JEB) | 105% | 23 |
| – | 2025-Q3 | JEB revenues increase | 11.3% | 23 |
| – | 2025-Q3 | Group revenues decrease | (7.1)% | 23 |
| – | 2025-Q3 | Gross margin (JEB) | 2.7 % | 23 |
| – | 2025-Q3 | Gross margin (Group) | 6.7 % | 23 |
| – | 2025-Q3 | Gross margin (D&PD) | 8.1 % | 23 |
| – | 2025-Q3 | Expected cost reduction in 2025 | more than € 60 m | 23 |
| – | 2025-Q3 | Equity ratio | 45.1% | 23 |
| – | 2025-H1 | Total Liquidity | 348.0 m | 24 |
| – | 2025-H1 | Gross margin Just - Evotec Biologics | 9.1% | 24 |
| – | 2025-H1 | Gross margin Discovery & Preclinical Development | 9.8% | 24 |
| – | 2025-H1 | Gross margin | 9.6% | 24 |
| – | 2025-H1 | Equity ratio | 46.8% | 24 |
| 2025-05-06 | 2025-Q1 | Proprietary R&D projects portfolio | over 100 | 27 |
| 2025-05-06 | 2025-Q1 | Global team size | more than 4,800 | 27 |
| 2025-05-06 | 2025-Q1 | BMS partnership payments | US$ 75 m | 27 |
| 2025-04-17 | 2025-Q1 | Priority Reset annualised recurring gross savings | 40 m | 19 |
| 2025-04-17 | 2025-Q1 | One-off costs Priority Reset | 54.9 m | 19 |
| 2025-04-17 | 2025-Q1 | Cost-out initiatives gross savings by 2028 | > 50 m | 19 |
| – | 2025-Q1 | Total liquidity | € 371.4 m | 22 |
| – | 2025-Q1 | Gross margin shared R&D | 10.8% | 22 |
| – | 2025-Q1 | Gross margin Just - Evotec Biologics | 20.2% | 22 |
| – | 2025-Q1 | gross margin group | 13.6% | 22 |
| – | 2025-Q1 | equity ratio | 46.9% | 22 |
| 2025-04-14 | FY2024 | property, plant & equipment, net | 686,438 | 20 |
| 2025-04-14 | FY2024 | prepaid expenses | 22,240 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | personnel expenses | 458,738 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | other current assets | 23,279 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | non-current contract liabilities | 156,679 | 20 |
| 2025-04-14 | FY2024 | net debt leverage ratio | 1.9x | 20 |
| 2025-04-14 | FY2024 | liquidity composition USD | 26% | 20 |
| 2025-04-14 | FY2024 | liquidity composition GBP | 12% | 20 |
| 2025-04-14 | FY2024 | liquidity composition EUR | 62% | 20 |
| 2025-04-14 | FY2024 | lease liabilities, non-current | 132,301 | 20 |
| 2025-04-14 | FY2024 | lease liabilities, current | 19,563 | 20 |
| 2025-04-14 | FY2024 | equity ratio | 50% | 20 |
| 2025-04-14 | FY2024 | depreciation PP&E | 95.1 m | 20 |
| 2025-04-14 | FY2024 | deferred tax liabilities | 14,516 | 20 |
| 2025-04-14 | FY2024 | deferred tax assets | 17,333 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | deferred income tax | 5,331 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | deferred income, current | 33,773 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | current income tax expense | (7,433) | 20 |
| 2025-04-14 | FY2024 | current contract liabilities | 106,599 | 20 |
| 2025-04-14 | FY2024 | Cost of materials | 122,044 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | Contract assets | 46,034 (EUR in k€) | 20 |
| 2025-04-14 | FY2024 | Bank loans fixed rate | 95% | 20 |
| 2025-04-14 | FY2024 | Year-end analyst target price | € 12.58 | 20 |
| 2025-04-14 | FY2024 | Unused credit lines | 75.1 m EUR | 20 |
| 2025-04-14 | FY2024 | Unpartnered projects eligible for partnering | 45 | 20 |
| 2025-04-14 | FY2024 | Triton GP HoldCo stake | 9.99% | 20 |
| 2025-04-14 | FY2024 | Top 10 customers contribution | 52% | 20 |
| 2025-04-14 | FY2024 | Syndicated loan facility | 250 m EUR | 20 |
| 2025-04-14 | FY2024 | Shares outstanding | 177,553,456 | 20 |
| 2025-04-14 | FY2024 | Share price trough 2024 | € 5.27 | 20 |
| 2025-04-14 | FY2024 | Share price at year start | € 21.28 | 20 |
| 2025-04-14 | FY2024 | Share price at year end | € 8.20 | 20 |
| 2025-04-14 | FY2024 | Scientific experts | 3,800 | 20 |
| 2025-04-14 | FY2024 | SG&A cost ratio | 24% | 20 |
| 2025-04-14 | FY2024 | Repeat business rate | 94% | 20 |
| 2025-04-14 | FY2024 | Repeat business | 94% | 20 |
| 2025-04-14 | FY2024 | R&D expenses ratio | 6% | 20 |
| 2025-04-14 | FY2024 | Projects in clinical trials | 6 | 20 |
| 2025-04-14 | FY2024 | Patent families owned | 45 | 20 |
| 2025-04-14 | FY2024 | Partnered projects | 75 | 20 |
| 2025-04-14 | FY2024 | Number of sites | 15 | 20 |
| 2025-04-14 | FY2024 | Customers contributing more than EUR 1m to revenue | 109 | 20 |
| 2025-04-14 | FY2024 | Number of Customers | 800 | 20 |
| 2025-04-14 | FY2024 | Number of analysts covering | 13 | 20 |
| 2025-04-14 | FY2024 | Novo Holdings stake | 8.4% | 20 |
| 2025-04-14 | FY2024 | New customers added | 292 | 20 |
| 2025-04-14 | FY2024 | Mubadala Investment Company stake | 6.6% | 20 |
| 2025-04-14 | FY2024 | Liquidity at year end | 396.8 m EUR | 20 |
| 2025-04-14 | FY2024 | Lease obligations | 151,864 | 20 |
| 2025-04-14 | FY2024 | Largest three customers contribution | 38% | 20 |
| 2025-04-14 | FY2024 | IFRS 16 ROU depreciation | 21.5 m | 20 |
| 2025-04-14 | FY2024 | Gross margin prior year | 22.4% | 20 |
| 2025-04-14 | FY2024 | Gross margin | 14.4% | 20 |
| 2025-04-14 | FY2024 | Free float | 75.0% | 20 |
| 2025-04-14 | FY2024 | Equity ratio | 49.8 % | 20 |
| 2025-04-14 | FY2024 | Equity attributable to shareholders of Evotec SE | 952,525 | 20 |
| 2025-04-14 | FY2024 | EURIBOR 3m | 2.7% | 20 |
| 2025-04-14 | FY2024 | EIB loan facility drawn | 93.3 m EUR | 20 |
| 2025-04-14 | FY2024 | Customers generating more than 1m EUR revenue | 109 (EUR millions) | 20 |
| 2025-04-14 | FY2024 | Customer retention rate | 90% or above | 20 |
| 2025-04-14 | FY2024 | Balance Sheet Total | 1,912,502 | 20 |
| 2025-04-14 | FY2024 | Average daily trading volume | 1,394,102 shares | 20 |
| 2025-04-14 | FY2024 | Analyst positive recommendations | 7 | 20 |
| 2025-04-14 | FY2024 | Analyst neutral recommendations | 2 | 20 |
| 2025-04-14 | FY2024 | Analyst negative recommendations | 4 | 20 |
| – | 2024-Q3 | Shared R&D revenue decline | (12)% | 14 |
| – | 2024-Q3 | Just-Evotec Biologics revenue growth | 74% | 14 |
| – | 2024-Q3 | Group revenue decline | (1)% | 14 |
| – | 2024-Q3 | Gross margin | 11.9% | 14 |
| – | 2024-Q3 | Adjusted Group EBITDA improvement (annualized) | over €40 m | 14 |
| – | 2024-H1 | Total Liquidity | 298.9 m | 13 |
| – | 2024-H1 | Gross margin | 12.9% | 13 |
| – | 2024-H1 | Equity ratio | 50.6% | 13 |
| – | 2024-H1 | Adjusted Group EBITDA Shared R&D | (3.8) m | 13 |
| – | 2024-H1 | Adjusted EBITDA Just-Evotec Biologics | 3.3 m | 13 |
| – | 2024-Q1 | Total Liquidity | 509.9 m | 12 |
| – | 2024-Q1 | Orders in Discovery | +70% | 12 |
| – | 2024-Q1 | Gross margin Shared R&D | 12.8% | 12 |
| – | 2024-Q1 | Gross margin Just-Evotec Biologics | 27.9% | 12 |
| – | 2024-Q1 | Gross margin | 16.7% | 12 |
| – | 2024-Q1 | Equity ratio | 50.1% | 12 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses 2023 | 64,818 (EUR k€) | 11 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses 2022 | 70,204 (EUR k€) | 11 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses 2021 | 58,117 (EUR k€) | 11 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses 2020 | 46,441 (EUR k€) | 11 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses 2019 | 37,477 (EUR k€) | 11 |
| 2024-04-22 | FY2023 | Treasury shares 31 December 2023 | 249,915 | 11 |
| 2024-04-22 | FY2023 | Total customers | 800 | 11 |
| 2024-04-22 | FY2023 | Top 3 customers revenue contribution % | 35 | 11 |
| 2024-04-22 | FY2023 | Top 10 customers revenue contribution % | 47 | 11 |
| 2024-04-22 | FY2023 | T. Rowe Price shareholding | 10.1 | 11 |
| 2024-04-22 | FY2023 | Share of women in management positions | 31.9 | 11 |
| 2024-04-22 | FY2023 | Scientists with academic qualification % | 86 | 11 |
| 2024-04-22 | FY2023 | Repeat business % | 93 | 11 |
| 2024-04-22 | FY2023 | registered share capital year end 2023 | 177,185,736 | 11 |
| 2024-04-22 | FY2023 | R&D expenses | 110 (EUR € m) | 11 |
| 2024-04-22 | FY2023 | projects with academia and biotech partners bridge since 2010 | 10 | 11 |
| 2024-04-22 | FY2023 | pipeline assets total | 140 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets small molecules | 90 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets phase II | 6 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets phase I | 10 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets multimodality early stage | 10 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets clinical development | 18 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets cell gene therapy | 10 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | pipeline assets biologics | 20 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | Novo Holdings shareholding | 9.8 | 11 |
| 2024-04-22 | FY2023 | new customers 2023 | 298 | 11 |
| 2024-04-22 | FY2023 | nationalities | 93 | 11 |
| 2024-04-22 | FY2023 | Mubadala Investment shareholding | 6.6 | 11 |
| 2024-04-22 | FY2023 | management shareholding | 1 | 11 |
| 2024-04-22 | FY2023 | free float | 72.5 | 11 |
| 2024-04-22 | FY2023 | EVT Innovate revenue contribution pct | 34 | 11 |
| 2024-04-22 | FY2023 | EVT Execute revenue contribution pct | 66 | 11 |
| 2024-04-22 | FY2023 | Evotec share price year end 2023 | 21.28 | 11 |
| 2024-04-22 | FY2023 | Evotec share price minimum 2023 | 15.74 | 11 |
| 2024-04-22 | FY2023 | Evotec share price maximum 2023 | 24.24 | 11 |
| 2024-04-22 | FY2023 | Evotec ADS performance 2023 | 45.0 | 11 |
| 2024-04-22 | FY2023 | Equity ratio prior year | 52.6 % | 11 |
| 2024-04-22 | FY2023 | equity ratio | 49.7 % | 11 |
| 2024-04-22 | FY2023 | Equity participations in breakthrough company formations | 93 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | Equity participations | 298 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | Equity attributable to shareholders prior year | 1,187,184 | 11 |
| 2024-04-22 | FY2023 | Equity attributable to shareholders | 1,119,908 | 11 |
| 2024-04-22 | FY2023 | Customers over 1M revenue | 102 (EUR millions) | 11 |
| 2024-04-22 | FY2023 | Co-owned products | 140 | 11 |
| 2024-04-22 | FY2023 | Capex investments over last 5 years | 641.6 (EUR € m) | 11 |
| 2024-04-22 | FY2023 | Balance sheet total prior year | 2,257,247 | 11 |
| 2024-04-22 | FY2023 | Balance sheet total | 2,252,468 | 11 |
| 2024-04-22 | FY2023 | Average daily trading volume | 428,679 | 11 |
| 2024-04-22 | FY2023 | Alliances | 838 | 11 |
| 2024-04-22 | FY2023 | AGM shareholder representation 2023 | 67.68 | 11 |
| 2024-04-22 | FY2023 | Work-in-progress (31 December 2022) | 1,908 | 11 |
| 2024-04-22 | FY2023 | Work-in-progress | 4,989 | 11 |
| 2024-04-22 | FY2023 | Unutilized lines of credit (31 December 2023) | 141,086 | 11 |
| 2024-04-22 | FY2023 | Unutilized lines of credit (31 December 2022) | 245,509 | 11 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses prior year | 70,204 (EUR in €k) | 11 |
| 2024-04-22 | FY2023 | Unpartnered R&D expenses | 64,818 (EUR in €k) | 11 |
| 2024-04-22 | FY2023 | USD cash flows hedged against GBP (31 December 2023) | 60,000 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | USD cash flows hedged against GBP (31 December 2022) | 44,400 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | USD cash flows hedged against Euro (31 December 2023) | 173,000 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | USD cash flows hedged against Euro (31 December 2022) | 350 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Total lease obligations (31 December 2022) | 176,823 | 11 |
| 2024-04-22 | FY2023 | Total lease obligations | 189,140 | 11 |
| 2024-04-22 | FY2023 | Total amount recognised in profit or loss (2023) | 27,205 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Total amount recognised in profit or loss (2022) | 23,026 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Short-term investments (31 December 2022) | 303,334 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Short-term investments | 93,203 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Share performance awards current service cost (2022) | 9,919 | 11 |
| 2024-04-22 | FY2023 | Share performance awards current service cost | 9,630 | 11 |
| 2024-04-22 | FY2023 | Salary increase - France (2023) | 3.00% | 11 |
| 2024-04-22 | FY2023 | Salary increase - France (2022) | 3.00% | 11 |
| 2024-04-22 | FY2023 | SPAs granted to Management Board (2022) | 139,229 | 11 |
| 2024-04-22 | FY2023 | SPAs granted to Management Board | 227,555 | 11 |
| 2024-04-22 | FY2023 | SPAs granted (2023) | 1,489 | 11 |
| 2024-04-22 | FY2023 | SPAs granted (2022) | 469 | 11 |
| 2024-04-22 | FY2023 | SPAs exercised (2022) | 344,458 | 11 |
| 2024-04-22 | FY2023 | SPAs exercised | 233,083 | 11 |
| 2024-04-22 | FY2023 | SPAs end of year 2023 | 2,761 | 11 |
| 2024-04-22 | FY2023 | SPAs end of year 2022 | 1,505 | 11 |
| 2024-04-22 | FY2023 | SG&A cost ratio prior year | 21% | 11 |
| 2024-04-22 | FY2023 | SG&A cost ratio | 22% | 11 |
| 2024-04-22 | FY2023 | Repeat business | 93% | 11 |
| 2024-04-22 | FY2023 | Remaining performance obligations (in the course of the year) | 571,825 | 11 |
| 2024-04-22 | FY2023 | Remaining performance obligations (after one year) | 335,427 | 11 |
| 2024-04-22 | FY2023 | Raw materials (31 December 2022) | 27,917 | 11 |
| 2024-04-22 | FY2023 | Raw materials | 25,901 | 11 |
| 2024-04-22 | FY2023 | Prepaid expenses (31 December 2022) | 16,948 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Prepaid expenses | 18,395 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Pipeline development | >140 assets | 11 |
| 2024-04-22 | FY2023 | Patent families | >50 | 11 |
| 2024-04-22 | FY2023 | Other current financial liabilities (31 December 2022) | 7,087 | 11 |
| 2024-04-22 | FY2023 | Other current financial liabilities | 10 | 11 |
| 2024-04-22 | FY2023 | Customers contributing more than EUR 1m to revenue | 102 | 11 |
| 2024-04-22 | FY2023 | Number of Customers | 838 | 11 |
| 2024-04-22 | FY2023 | Net debt ratio with IFRS 16 | (6.2)x | 11 |
| 2024-04-22 | FY2023 | Net debt ratio | 0.4x | 11 |
| 2024-04-22 | FY2023 | Maintenance fees (31 December 2023) | 376 | 11 |
| 2024-04-22 | FY2023 | Maintenance fees (31 December 2022) | 1,483 | 11 |
| 2024-04-22 | FY2023 | Long-term lease obligations (31 December 2022) | 161,998 | 11 |
| 2024-04-22 | FY2023 | Long-term lease obligations | 169,487 | 11 |
| 2024-04-22 | FY2023 | Liquidity prior year | 718.5 m | 11 |
| 2024-04-22 | FY2023 | Liquidity | 604.1 m | 11 |
| 2024-04-22 | FY2023 | Lease liabilities current portion (31 December 2022) | 14,825 | 11 |
| 2024-04-22 | FY2023 | Lease liabilities current portion | 19,653 | 11 |
| 2024-04-22 | FY2023 | Investments measured at fair value (31 December 2022) | 131,042 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Investments measured at fair value | 35,593 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Interest expense on lease liability (2023) | 5,832 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Interest expense on lease liability (2022) | 3,841 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Gross margin prior year | 23.2% | 11 |
| 2024-04-22 | FY2023 | Gross margin | 22.4% | 11 |
| 2024-04-22 | FY2023 | Granted SPAs at beginning of 2023 | 1,505 | 11 |
| 2024-04-22 | FY2023 | Granted SPAs at beginning of 2022 | 1,325 | 11 |
| 2024-04-22 | FY2023 | Flexible interest rate sensitivity -1% (2023) | -2,495 | 11 |
| 2024-04-22 | FY2023 | Flexible interest rate sensitivity -1% (2022) | -1,714 | 11 |
| 2024-04-22 | FY2023 | Flexible interest rate sensitivity +1% (2023) | 3,794 | 11 |
| 2024-04-22 | FY2023 | Flexible interest rate sensitivity +1% (2022) | 3,014 | 11 |
| 2024-04-22 | FY2023 | FX derivative gain (2023) | 8,360 | 11 |
| 2024-04-22 | FY2023 | FX derivative gain (2022) | 9,424 | 11 |
| 2024-04-22 | FY2023 | Expense relating to short-term leases (2023) | 236 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Expense relating to short-term leases (2022) | 476 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Expense for leases on an asset of low value (2023) | 62 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Expense for leases on an asset of low value (2022) | 50 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Expected credit loss on cash and cash equivalents and short-term investments | 225 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Equity ratio prior year | 53% | 11 |
| 2024-04-22 | FY2023 | Equity ratio | 50% | 11 |
| 2024-04-22 | FY2023 | EVT Innovate gross margin prior year | 28.9% | 11 |
| 2024-04-22 | FY2023 | EVT Innovate gross margin | 30.8% | 11 |
| 2024-04-22 | FY2023 | EVT Execute gross margin prior year | 17.7% | 11 |
| 2024-04-22 | FY2023 | EVT Execute gross margin excluding Just-Evotec Biologics | 17.9% | 11 |
| 2024-04-22 | FY2023 | EVT Execute gross margin | 14.5% | 11 |
| 2024-04-22 | FY2023 | EUR cash outflows hedged against GBP (31 December 2023) | 3,900 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | EUR cash outflows hedged against GBP (31 December 2022) | 8,400 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | EIB facility agreement drawn amount (31 December 2023) | 93,290 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Discount rate - France (2023) | 3.25% | 11 |
| 2024-04-22 | FY2023 | Discount rate - France (2022) | 3.35% | 11 |
| 2024-04-22 | FY2023 | Depreciation of property, plant and equipment prior year | 72.7 m | 11 |
| 2024-04-22 | FY2023 | Depreciation of property, plant and equipment | 86.0 m | 11 |
| 2024-04-22 | FY2023 | Depreciation expense of right-of-use (2023) | 21,075 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Depreciation expense of right-of-use (2022) | 18,659 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Customer retention rate | 93% | 11 |
| 2024-04-22 | FY2023 | Current portion of lease obligations (31 December 2022) | 14,825 | 11 |
| 2024-04-22 | FY2023 | Current portion of lease obligations | 19,115 | 11 |
| 2024-04-22 | FY2023 | Current loan liabilities (31 December 2022) | 1,556 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Current loan liabilities | 129,971 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Current financial liabilities (31 Dec 2022) | 23,468 | 11 |
| 2024-04-22 | FY2023 | Current financial liabilities | 149,096 | 11 |
| 2024-04-22 | FY2023 | Contract liabilities (non-current) | 155,287 | 11 |
| 2024-04-22 | FY2023 | Contract liabilities (current) | 97,587 | 11 |
| 2024-04-22 | FY2023 | Contract assets | 25,000 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Cash outflows for leases (2023) | 22,446 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Cash outflows for leases (2022) | 19,046 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Cash and cash equivalents and investments (31 Dec 2022) | 718,489 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Cash and cash equivalents and investments | 604,112 (EUR in k€) | 11 |
| 2024-04-22 | FY2023 | Bonus accruals (31 Dec 2023) | 13,817 | 11 |
| 2024-04-22 | FY2023 | Bonus accruals (31 Dec 2022) | 26,704 | 11 |
| 2024-04-22 | FY2023 | Avg. weighted share price at exercise date (2023) | 19.38 | 11 |
| 2024-04-22 | FY2023 | Avg. weighted share price at exercise date (2022) | 34.27 | 11 |
| 2024-04-22 | FY2023 | Audit fees (31 Dec 2023) | 1,964 | 11 |
| 2024-04-22 | FY2023 | Audit fees (31 Dec 2022) | 2,111 | 11 |
| 2024-04-22 | FY2023 | Allowance for expected credit losses - expected default rates (31 Dec 2022) | 0.078% and 16.758% | 11 |
| 2024-04-22 | FY2023 | Allowance for expected credit losses - expected default rates | 0.010% and 4.020% | 11 |
| 2024-04-22 | FY2023 | Accrued vacation (31 Dec 2023) | 18,454 | 11 |
| 2024-04-22 | FY2023 | Accrued vacation (31 Dec 2022) | 16,637 | 11 |
| 2023-09-30 | 2023-Q3 | Unpartnered R&D expenses prior year | 50,700 (EUR in T€) | 4 |
| 2023-09-30 | 2023-Q3 | unpartnered R&D expenses | 45,700 (EUR in T€) | 4 |
| 2023-09-30 | 2023-Q3 | total liquidity prior year | 718.5 m | 4 |
| 2023-09-30 | 2023-Q3 | Total liquidity | 613.4 m | 4 |
| 2023-09-30 | 2023-Q3 | net debt leverage ratio | (2.8)x adjusted EBITDA excl. IFRS 16 effect, (4.6)x incl. IFRS 16 | 4 |
| 2023-09-30 | 2023-Q3 | gross margin prior year | 17.9% | 4 |
| 2023-09-30 | 2023-Q3 | gross margin | 23.7% | 4 |
| 2023-09-30 | 2023-Q3 | DSO days | 63 | 4 |
| 2023-08-29 | 2023-H1 | weighted average shares outstanding | 176,935,744 | 10 |
| 2023-08-29 | 2023-H1 | Total liquidity | 620.8 m | 10 |
| 2023-08-29 | 2023-H1 | net debt leverage ratio incl. IFRS 16 | (0.9)x | 10 |
| 2023-08-29 | 2023-H1 | net debt leverage ratio excl. IFRS 16 | (3.6)x | 10 |
| 2023-08-29 | 2023-H1 | gross margin % | 25.9% | 10 |
| 2023-08-29 | 2023-H1 | equity ratio | 51.0% | 10 |
| 2023-08-29 | 2023-H1 | days sales outstanding | 62 | 10 |
| 2023-08-29 | 2023-H1 | adjusted group EBITDA H1 2023 | 26.1 m | 10 |
| 2023-08-29 | 2023-H1 | potential partnership milestones | >50 | 3 |
| 2023-08-29 | 2023-H1 | net debt ratio (31 Dec 2022) | (2.1) | 3 |
| 2023-08-29 | 2023-H1 | net debt ratio | (0.9) | 3 |
| 2023-08-29 | 2023-H1 | liquidity position (31 Dec 2022) | 718.5 | 3 |
| 2023-08-29 | 2023-H1 | liquidity position | 620.8 | 3 |
| 2023-08-29 | 2023-H1 | Just - Evotec Biologics sales order book | >850 | 3 |
| 2023-08-29 | 2023-H1 | gross margin excl. JEB (H1 2022) | 27.3 | 3 |
| 2023-08-29 | 2023-H1 | gross margin excl. JEB | 25.3 | 3 |
| 2023-08-29 | 2023-H1 | gross margin Innovate | 31.0% | 7 |
| 2023-08-29 | 2023-H1 | Gross margin Group prior year | 18.8% | 7 |
| 2023-08-29 | 2023-H1 | Gross margin Group | 25.9% | 7 |
| 2023-08-29 | 2023-H1 | Gross margin Execute | 25.7% | 7 |
| 2023-08-29 | 2023-H1 | Gross margin (H1 2022) | 18.8 | 3 |
| 2023-08-29 | 2023-H1 | Gross margin | 25.9 | 3 |
| 2023-08-29 | 2023-H1 | Equity ratio (31 Dec 2022) | 52.6 | 3 |
| 2023-08-29 | 2023-H1 | Equity ratio | 51.0 | 3 |
| 2023-08-29 | 2023-H1 | Co-owned projects | >140 | 3 |
| 2023-08-29 | 2023-H1 | Clinical stage co-owned pipeline assets | 25 (EUR millions) | 3 |
| 2023-08-29 | 2023-H1 | Balance sheet total (31 Dec 2022) | 2,257.2 | 3 |
| 2023-08-29 | 2023-H1 | Balance Sheet Total | 2,301.2 | 3 |
| 2023-08-29 | 2023-H1 | Average royalty rate | >45 | 3 |
| – | 2023-H1 | Net debt leverage ratio (excl. IFRS 16) | (3.6)x | 5 |
| – | 2023-H1 | Gross margin | 25.9% | 5 |
| – | 2023-H1 | Equity ratio | 51.0% | 5 |
| – | 2023-H1 | Days Sales Outstanding | 62 | 5 |
| 2023-05-15 | 2023-Q1 | Unpartnered R&D 2022 | € 70.2 m | 1 |
| 2023-05-15 | 2023-Q1 | Revenue 2022 | € 751.4 m | 1 |
| 2023-05-15 | 2023-Q1 | Adj. EBITDA 2022 | € 101.7 m | 1 |
Advertisement
Guidance Tracking (latest per metric/period · 12/26)#
All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.
Actuals: revenue in €m
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2030 | – | Revenue | 1,000 | – | pending | initiated | 32 |
| FY2028 | 2025-04-17 | EBITDA margin | 20% | – | pending | initiated | 27 |
| FY2028 | – | Group revenues CAGR | 8–12% | – | pending | initiated | 24 |
| FY2026 | 2026-03-31 | Revenue | moderate year-on-year revenue decline in the high single-digit percentage range | – | pending | cut | 29 |
| FY2026 | 2026-03-31 | EBITDA (adjusted) | -35–-25 | – | pending | cut | 29 |
| FY2026 | 2026-03-31 | Liquidity | 85 | – | pending | cut | 29 |
| FY2026 | 2026-03-31 | R&D expenses | 45–55 | – | pending | initiated | 29 |
| FY2025 | 2026-03-31 ° | Revenue | 788.4 | 788.4 | in line | confirmed | 29 |
| FY2025 | 2026-03-31 ° | EBITDA (adjusted) | 41.1 | -12 | miss | confirmed | 29 |
| FY2025 | 2025-04-17 | R&D expenditures | 40–50 | – | – | – | 26 |
| FY2025 | 2025-04-14 | liquidity | 100 | – | – | initiated | 20 |
| FY2025 | 2025-04-14 | R&D expenses | 40–50 | – | – | initiated | 20 |
| FY2024 | 2025-04-14 ° | Revenue | 790–820 | 797 | in line | revised | 20 |
| FY2024 | 2025-04-14 ° | EBITDA (adjusted) | 15–35 | 9.9 | miss | revised | 20 |
| FY2024 | 2025-04-14 ° | Unpartnered R&D expenses | 50–60 | – | – | revised | 20 |
| FY2024 | 2024-04-22 | Evotec SE liquidity | 230 | – | – | initiated | 11 |
| FY2024 | – | Capex | 50–60 | – | – | confirmed | 13 |
| FY2024 | – | R&D expenditures | 50–60 | – | – | confirmed | 14 |
| FY2023 | 2023-09-30 | EBITDA (adjusted) | 60–90 | 66.4 | in line | confirmed | 4 |
| FY2023 | 2023-08-29 | Revenue | 750–805 | 781.4 | in line | confirmed | 4 |
| FY2023 | 2023-08-29 | unpartnered_rd_expenses | 60–70 | – | – | confirmed | 4 |
| FY2023 | 2023-08-29 | Group revenues (at constant fx-rates) | 765–805 | – | – | confirmed | 3 |
| FY2023 | 2023-08-29 | Unpartnered R&D | 60–70 | – | – | confirmed | 3 |
| FY2023 | 2023-08-29 | Unpartnered R&D expenses | 60–70 | – | – | confirmed | 7 |
| FY2023 | 2023-05-15 | Capex | 70–80 | 213.3 | beat | confirmed | 1 |
| FY2023 | – | Unpartnered research and development expenses | 60–70 | – | – | confirmed | 5 |
Advertisement
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.
FY2026
In the first half of fiscal year 2026, Evotec reported group revenues of €300.1m, a decrease of 19.2% year-on-year, driven by weak sales conversion across business areas and a challenging market environment 31. Q1 2026 revenues amounted to 156.6m, declining 22%, with a 15% decline in the D&PD segment and a 38% decline in Just-Evotec Biologics, the latter partly attributable to the prior-year $25m Sandoz license base effect 32; Q2 revenues were 143.5m 133. In March 2026, Evotec initiated Project Horizon, a strategic transformation targeting consolidation to 10 sites with expected €75m run-rate savings by end of 2027, which resulted in €98.9m of reorganization charges recognized in H1 2026 31. The sale of Tubulis GmbH to Gilead Sciences closed on May 21, 2026 for gross proceeds of €93.652m 31. Following revenue shortfalls, full-year guidance was cut to €570-610m revenues and adjusted EBITDA of €(70)-(105)m from prior guidance of €700-780m and €0-40m respectively 31.
FY2025
Evotec SE reported full-year 2025 group revenues of 788.4m, slightly lower year on year, as a 13.5% decline in Discovery & Preclinical Development revenues to €528.9m 29 was only partially offset by a 39.7% increase in Just – Evotec Biologics revenues to €259.4m, largely driven by the landmark Sandoz transaction 29. The full-year net loss narrowed to 103.5m from €196.1m in 2024, primarily because the large reorganisation charges from the Priority Reset programme did not recur in 2025 29. Adjusted Group EBITDA improved to €41.1m from €22.6m in 2024 29, finishing within the revised full-year guidance range. The defining corporate event was the sale of Just – Evotec Biologics EU SAS to Sandoz AG, which closed in December 2025 and moved the company from a net debt to a net cash position 29. Post year-end, Evotec announced the Horizon transformation initiative in March 2026, targeting a reduction from 14 to 10 global sites and run-rate savings of €75m by end of 2027 29.
FY2024
Evotec SE reported full-year 2024 revenues of 797 million, up 2% year-on-year 20, as 71% growth in Just-Evotec Biologics offset a decline in Shared R&D 20. Adjusted Group EBITDA declined 66% to €22.6 million 20, while the operating result was a loss of 142.5 million, including €54.9 million in reorganisation costs related to a priority reset program targeting approximately 400 headcount reductions, site closures and exit from gene therapy activities 20. Net loss for the year totalled 196.1 million 20; cash and equivalents declined from €510.9 million at year-end 2023 to 306.4 million, reflecting capital expenditure of 117.5 million primarily for the second J.POD biologics facility in Toulouse 20. A €250 million senior secured revolving credit facility was secured in July 2024 and covenant waivers from RCF lenders were obtained until 30 June 2025; the J.POD Toulouse facility celebrated its grand opening in September 2024 and is scheduled to begin operations in 2025 20. Group footprint was reduced from 17 to 15 sites in eight countries, with 4,827 employees at year-end 2024 20.
FY2023
Evotec SE reported full-year 2023 group revenue of 781.4 million, a 4% increase from €751.4 million in 2022, achieved despite a criminal cyber-attack on 6 April 2023 that disrupted operations through Q2 and into Q3, causing approximately €43.5 million in direct costs over the full year 11. Q1 2023 was described as the strongest quarter in Evotec's history, while Q2 revenue of 170.3 million was materially reduced by the cyber incident, which caused approximately €70 million in missed net revenues and approximately €90 million impact on full-year adjusted Group EBITDA 3. Three significant strategic partnerships were established or expanded during the year: an eight-year extension of the Bristol Myers Squibb neuroscience programme, a new oncology collaboration with Janssen Biotech, and a biosimilar technology partnership between Just – Evotec Biologics and Sandoz 11. Adjusted Group EBITDA decreased to €66.4 million from €101.7 million in 2022, and the full-year operating result was a loss of 47.5 million; the net loss narrowed to 83.9 million from €175.7 million in 2022, with sources attributing the improvement primarily to better non-operating investment results – the prior year had included approximately €97.7 million in investment revaluation losses – rather than operational performance 10 11.
Advertisement
Glossary#
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Advertisement
Sources: official investor relations documents#
All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.
33 documents · 2023 – 2026 · IR
| # | Document type | Published | Link |
|---|---|---|---|
| #4 | IR-Quarter | – | Open |
| #5 / #105 | IR-Half | – | Open |
| #9 | IR-Report | – | Open |
| #12 / #114 | IR-Half | – | Open |
| #13 / #115 | IR-Half | – | Open |
| #14 / #116 | IR-Half | – | Open |
| #15 | IR-Report | – | Open |
| #16 | IR-Report | – | Open |
| #22 / #124 | IR-Half | – | Open |
| #23 / #125 | IR-Half | – | Open |
| #24 / #126 | IR-Half | – | Open |
| #28 | IR-Report | – | Open |
| #29 / #131 | IR-Annual | – | Open |
| #30 | IR-Report | – | Open |
| #31 / #133 | IR-Half | – | Open |
| #32 / #134 | IR-Quarter | – | Open |
| #2 | IR-Quarter | 2023-05-12 | Open |
| #1 | IR-Quarter | 2023-05-15 | Open |
| #6 | IR-Half | 2023-08-28 | Open |
| #3 / #103 | IR-Half | 2023-08-29 | Open |
| #7 | IR-Half | 2023-08-29 | Open |
| #10 / #112 | IR-Report | 2023-08-29 | Open |
| #8 | IR-Report | 2023-11-01 | Open |
| #11 / #113 | IR-Annual | 2024-04-22 | Open |
| #17 | IR-Half | 2024-08-07 | Open |
| #18 | IR-Quarter | 2024-10-30 | Open |
| #20 / #122 | IR-Annual | 2025-04-14 | Open |
| #19 | IR-Quarter | 2025-04-17 | Open |
| #27 | IR-Report | 2025-05-06 | Open |
| #25 | IR-Half | 2025-08-06 | Open |
| #26 | IR-Half | 2025-08-13 | Open |
| #21 | IR-Report | 2025-10-29 | Open |
| #33 | IR-Report | 2026-04-01 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Where can I find the official investor relations documents of Evotec SE?
The sources chapter links all 47 original filings used (IR documents) with type, publication date and a direct link; every figure in the report carries a source number.
More reports#
Recently updated
Same sector and country
Advertisement